Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare†or the "Company†) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares†and the holders of the Common Shares, the "Shareholders†) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly "Xeno†) a non- profit biotechnology company, b. ...